Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)

Category Primary study
JournalBRITISH JOURNAL OF DERMATOLOGY
Year 2024
This article has no abstract
Epistemonikos ID: 2205fc8e56fbf7ad9fe302caff7fc3ce1f09b7fd
First added on: Feb 18, 2025